Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents

NCT03332095 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

55

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Doravirine (DOR)
DRUG: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF)
DRUG: Antiretroviral (ARV) medications

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)